West Expands Manufacturing Capacity at Scottsdale Facility
News Jul 24, 2015
West Pharmaceutical Services, Inc. has announced that it has expanded capabilities at its Scottsdale, Ariz. facility to meet increased customer demand for the SmartDose® Electronic Wearable Injector.
The expansion in Scottsdale will enable continuing development and production of SmartDose to accommodate rising interest in the product to further demonstrate the ability to support customer launch plans and to provide supply-chain security.
"Expanding our manufacturing capabilities in Scottsdale - and continuing scaling up production in Israel - will enable rapid, dual sourcing to our customers and help them bring innovative new treatments to market," said Eric Resnick, President, Pharmaceutical Delivery Systems, Proprietary Products at West.
With the treatment of many chronic illnesses shifting out of clinical settings to home care and self-administration, there is growing need for drug products that can be easily injected by patients. Designed to deliver high volumes of injectable drugs over an extended period of time, SmartDose makes it easier for patients to self-administer medication and encourages compliance with prescribed treatments.
Patients have already self-administered thousands of doses using SmartDose in clinical settings. West has delivered more than 100,000 units of SmartDose and more than 800,000 validated Daikyo Crystal Zenith® drug containers to pharmaceutical manufacturers for customer-funded development projects and clinical trials, including eight active programs at various stages of pre-commercial development.
"Medication adherence is an ongoing challenge in the pharmaceutical industry, and non-adherence is a leading cause of poor clinical outcomes and increased healthcare costs," Resnick said. "We designed SmartDose to be an easy-to-use, intuitive and reliable drug delivery system that can help boost adherence for injectable medications – and the customer response has been tremendous."
The expanded capabilities at the Scottsdale site include clean room manufacturing and additional laboratory space. New jobs are being created in R&D, engineering, quality and operations functions to ramp-up production, new development and sustainment engineering.
The silicone-free Daikyo Crystal Zenith drug container that is used within SmartDose is commercially available in the ready-to-use format, and the combined offering provides system reliability and accountability from one partner.
West's commitment to all phases of component and delivery system manufacturing ensures that the same high standards of quality are applied to products from development all the way to commercialization.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018